Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Profile Name||JAK2 loss|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|JAK2 loss||melanoma||sensitive||VSV-delta51||Preclinical - Cell line xenograft||Actionable||In a preclinical study, treatment with VSV-delta51 resulted in decreased cell viability in melanoma cell lines with a loss of JAK2 in culture, and resulted in an increased median survival in a syngeneic mouse model grafted with a CRISPR-mediated JAK2 knockout melanoma cell line (PMID: 33593882).||33593882|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|